

Impact on Cost of Care of Concomitant Prescribing of Acid Reducing Agents with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: A US Payer Perspective

Adrian Kilcoyne^{1*}, Ramaa Nathan², Carlton Anderson¹, Alex Moore², Pierantonio Russo²

¹Xspray Pharma, Solna, Sweden

²EVERSANA Life Science Services, LLC, Kansas, USA

Corresponding author: Adrian Kilcoyne, EVERSANA Life Science Services, LLC, Kansas, USA, E-mail: adrian.kilcoyne@xspray.com

Received date: April 28, 2025, Manuscript No. IPJHME-25-20347; **Editor assigned date:** April 30, 2025, PreQC No. IPJHME-25-20347 (PQ); **Reviewed date:** May 14, 2025, QC No. IPJHME-25-20347; **Revised date:** May 21, 2025, Manuscript No. IPJHME-25-20347 (R); **Published date:** May 28, 2025, DOI: 10.36648/2471-9927.11.1.102

Citation: Kilcoyne A, Nathan R, Anderson C, Moore A, Russo P (2025) Impact on Cost of Care of Concomitant Prescribing of Acid Reducing Agents with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: A US Payer Perspective. J Health Med Econ Vol.11 No.1:102.

Supplementary Materials

Supplementary Table 1: Demographics of total population.

	Patients on TKI only (%)	Patients on TKI + any concomitant ARA (%)
Age		
18–34	10	4.5
35–44	12.4	7.9
45–55	18	15.3
55–84	24.9	27
85+	34.6	45.3
Gender		
Male	54.9	49.3
Female	45.1	50.7
ECI Score		
Negligible (<2)	62.5	50.6
Low (2–5)	15.8	19.3
Medium (6–10)	9.3	11.5
High (11–15)	6.6	8.9
Severe (>15)	5.7	9.6